publication date: Jan. 11, 2019

In Brief José Baselga heads to AstraZeneca amid organizational changes

José Baselga was appointed to a key role in driving scientific innovation in oncology at AstraZeneca, the company said.

Changes at the British-Swedish company include:

Therapy area-focused research and development units that are responsible for discovery through to late-stage development—one for oncology and one for BioPharmaceuticals (cardiovascular, renal & metabolism and respiratory)–with dynamic resource allocation across the company’s pipeline.

Mirrored commercial units—one for oncology and one for BioPharmaceuticals. The creation of the BioPharmaceuticals commercial unit aligns product strategy and commercial delivery across CVRM and respiratory.

The research and development units and the commercial units will each be represented on the senior executive team of AstraZeneca and report to CEO Pascal Soriot.

The units will also share common basic biology and science platforms as well as product supply, manufacturing and IT infrastructure to improve efficiency, the company said. These resources will continue to be allocated on a company-wide basis according to the overall therapy area considerations and strategy, the company said.

The research and development unit for oncology will be led by Baselga, who resigned from MSKCC position after revelations that he had failed to disclose conflicts of interest in his talks and publications (The Cancer Letter, Sept. 14, 2018). Recently, Baselga was asked … Continue reading José Baselga heads to AstraZeneca amid organizational changes

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2018 The Cancer Letter Inc.